Page 177 - SAMRC AnnualReport 2025-26
P. 177
P E R FOR M A NC E I N FOR M A T I ON
SAMVAC-mRNA Technology Transfer Programme
mRNA PROGRAMME PARTNERS AND SUPPORTERS
mRNA PROGRAMME FUNDERS
The mRNA Technology Transfer Programme, companies, with the main aim being to drive the
established by the WHO in partnership with MPP research, development and testing of mRNA vaccine
in 2021, has three objectives being executed by candidates, focusing on the priority diseases of
Afrigen (establishment and transfer of mRNA South Africa and Africa. Each consortium member
vaccine manufacturing capability), Biovac plays a critical role in the product development
(establishment of commercial mRNA vaccine value chain and a key goal has been to fill any
manufacturing capability) and the SAMRC existing gaps and ensure that South Africa has the
(establishment of an mRNA R&D programme). The capability to take an mRNA vaccine candidate all
latter is being executed by the South African mRNA the way through the product development process
Vaccine Consortium (SAMVAC), established in 2022 from identification of the immunogens to first in
with a total of 11 consortium members that include human studies.
public universities, science councils and private
SA M R C A N N U A L R EP O R T 2 0 2 5 / 2 0 2 6 175
